E3013
N-Ethyl-N-(3-sulfopropyl)-m-anisidine sodium salt
≥98%
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
Linear Formula:
C12H18NO4SNa
CAS Number:
Molecular Weight:
295.33
MDL number:
UNSPSC Code:
12352100
PubChem Substance ID:
NACRES:
NA.22
Pricing and availability is not currently available.
Recommended Products
Quality Level
assay
≥98%
storage temp.
2-8°C
SMILES string
[Na].CCN(CCCS(O)(=O)=O)c1cccc(OC)c1
InChI
1S/C12H19NO4S.Na/c1-3-13(8-5-9-18(14,15)16)11-6-4-7-12(10-11)17-2;/h4,6-7,10H,3,5,8-9H2,1-2H3,(H,14,15,16);/q;+1/p-1
InChI key
MWFOPMKUGZLPQA-UHFFFAOYSA-M
Related Categories
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Hui Zhang et al.
Cancer letters, 350(1-2), 61-68 (2014-04-22)
AST1306, an inhibitor of EGFR and ErbB2, is currently in phase I of clinical trials. We evaluated the effect of AST306 on the reversal of multidrug resistance (MDR) induced by ATP-binding cassette (ABC) transporters. We found that AST1306 significantly sensitized
Jurjen M Ruben et al.
Cancer immunology, immunotherapy : CII, 63(4), 335-345 (2014-01-05)
Since few leukemia-associated antigens (LAA) are characterized for acute myeloid leukemia (AML), apoptotic tumor cells constitute an attractive LAA source for DC-based vaccines, as they contain both characterized and unknown LAA. However, loading DC with apoptotic tumor cells may interfere
Thiruganesh Ramasamy et al.
Journal of biomedical nanotechnology, 10(7), 1304-1312 (2014-05-09)
Combination of two or more drugs has emerged as a promising strategy to elicit synergistic therapeutic responses that can overcome multidrug resistance of cancer cells at various stages of the growth cycle. In the current study, we investigated the efficacy
Hann Wang et al.
ACS nano, 9(3), 3332-3344 (2015-02-18)
Combination chemotherapy can mediate drug synergy to improve treatment efficacy against a broad spectrum of cancers. However, conventional multidrug regimens are often additively determined, which have long been believed to enable good cancer-killing efficiency but are insufficient to address the
Florence Joly et al.
BJU international, 115(1), 65-73 (2013-11-05)
To evaluate the overall benefits of non-taxane chemotherapies in a non-selected population including unfit patients presenting with symptoms and pain. This randomized phase II study reports data from 92 patients (52% >70 years old; 40% with a performance score of
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
